Pharmacovigilance companies exist to protect patients by monitoring drug safety signals, processing adverse event reports, and maintaining compliance with FDA, EMA, and ICH regulatory requirements. The work is technically demanding and deadline-driven — expedited adverse event reports must reach regulatory agencies within strict timeframes, and aggregate safety reports follow fixed calendar schedules. Behind this technical operation sits a dense administrative infrastructure: billing management, safety report coordination logistics, agency communications, and documentation maintenance. In 2026, pharmacovigilance companies are increasingly deploying virtual assistants to manage that infrastructure, allowing safety professionals to remain focused on signal detection and regulatory decision-making.
The Administrative Burden in Pharmacovigilance
Pharmacovigilance operates in a regulated environment with zero tolerance for administrative failure. A missed submission deadline can trigger regulatory action; a documentation gap in an adverse event file can create compliance risk. Yet much of the day-to-day administrative work in PV — billing reconciliation, report tracking, routine correspondence management, document archiving — does not inherently require the expertise of a trained pharmacovigilance professional.
According to the 2025 Drug Safety Operations Benchmarking Report published by the Drug Information Association, pharmacovigilance professionals in consulting and contract service environments spent an average of 10 to 14 hours per week on administrative tasks outside their core safety science responsibilities. As client portfolios grow and regulatory obligations multiply, this overhead compounds rapidly.
Billing in pharmacovigilance consulting is often structured around case volume, periodic report deliverables, and retainer arrangements for ongoing pharmacovigilance services. Managing billing accurately across variable case volumes and fixed regulatory reporting schedules requires consistent administrative attention that most safety scientists are not positioned to provide without cost to their primary work.
How Virtual Assistants Support PV Operations
Virtual assistants in pharmacovigilance companies are most commonly deployed across four administrative functions: client billing administration, safety report coordination, FDA and EMA communications management, and adverse event documentation.
Billing administration is a direct value-add. VAs track case processing volumes against client contract terms, prepare invoices aligned to deliverable completions or monthly retainer schedules, monitor accounts receivable, and issue payment follow-ups. They reconcile billing records against case management system data, reducing the invoice disputes that can arise when billing documentation is generated separately from operational records.
Safety report coordination support is a high-impact VA function. Periodic Benefit-Risk Evaluation Reports, Development Safety Update Reports, and Periodic Safety Update Reports all follow structured preparation and submission timelines. VAs maintain report calendars, alert teams to approaching deadlines, coordinate cross-functional preparation calls, distribute draft documents for internal review, and track submission confirmations — without touching the scientific content itself.
FDA and EMA communications generate a steady volume of administrative correspondence. VAs manage acknowledgment tracking for ICSRs submitted via MedWatch or EudraVigilance, log agency query receipts and response deadlines, coordinate logistics for regulatory meetings, and distribute agency communications to the appropriate internal teams. Technical responses are drafted by safety professionals; VAs manage the surrounding correspondence infrastructure.
Adverse event documentation management is critical to regulatory defensibility. VAs maintain case file archives, ensure all supporting documents are correctly linked to individual case safety reports, track corrective action logs, and verify that finalized cases are archived in compliant, audit-ready repositories.
The Forces Driving VA Adoption in 2026
Several dynamics are accelerating VA adoption among pharmacovigilance companies. Global PV regulatory requirements have expanded significantly in recent years, with ICH E2E, E2F, and regional guidances increasing the documentation burden across the product lifecycle. Companies serving multiple markets now manage parallel reporting obligations that multiply administrative workload.
Simultaneously, the market for experienced pharmacovigilance professionals remains tight. Hiring a full-time project administrator in a PV environment requires either a specialist with safety science background — expensive — or general administrative staff who must be extensively trained on regulatory requirements. Virtual assistants with professional services and regulated industry experience offer a more cost-effective and faster-to-deploy alternative.
Elena Torres, director of operations at a mid-size pharmacovigilance consulting firm, told Drug Safety Today in 2025 that deploying VAs for billing and report coordination "allowed our safety scientists to focus entirely on case processing and signal detection — our aggregate report delivery rate improved to 100 percent on-time within the first quarter."
Evaluating VA Providers for PV Companies
Pharmacovigilance companies require VAs who can handle sensitive safety data and regulatory correspondence with strict confidentiality and attention to detail. Familiarity with regulated documentation environments, professional services billing, and deadline-driven workflow management are key selection criteria.
Data security and NDA frameworks must be established before any VA engagement begins. Adverse event case data, sponsor proprietary information, and regulatory agency correspondence all require clear protective commitments from any administrative support provider.
Companies looking to scale administrative capacity in their PV operations can explore Stealth Agents, which provides trained virtual assistants with experience supporting life sciences and regulated professional services environments.
The Road Ahead
Pharmacovigilance obligations will continue to grow as regulatory agencies intensify post-market surveillance requirements and product portfolios expand. Companies that deploy structured VA support for billing, coordination, communications, and documentation will be better positioned to absorb that growth without proportional increases in overhead — and without diverting their safety professionals from the work that directly protects patients.
Sources:
- Drug Information Association, 2025 Drug Safety Operations Benchmarking Report
- Drug Safety Today, "Administrative Efficiency in PV Operations," 2025
- ICH Pharmacovigilance Guidelines Overview, 2025 Update